# Estramustine, Docetaxel and Zoledronate Treatment in Hormone-Refractory Adenocarcinoma of the Prostate

> **NCT00151073** · PHASE2 · COMPLETED · sponsor: **University of Michigan Rogel Cancer Center** · enrollment: 28 (actual)

## Conditions studied

- Hormone-Refractory Prostate Cancer

## Interventions

- **DRUG:** Zoledronic acid
- **DRUG:** Estramustine
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT00151073
- **Lead sponsor:** University of Michigan Rogel Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-04
- **Primary completion:** 2005-09
- **Final completion:** 2007-09
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2015-01-22

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00151073

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00151073, "Estramustine, Docetaxel and Zoledronate Treatment in Hormone-Refractory Adenocarcinoma of the Prostate". Retrieved via AI Analytics 2026-09-09 from https://api.ai-analytics.org/clinical/NCT00151073. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*